Kook Peter H
Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
J Vet Intern Med. 2025 Sep-Oct;39(5):e70188. doi: 10.1111/jvim.70188.
No data after hospitalization for acute pancreatitis (AP) in dogs comparing clinical signs to lipase results exists.
Evaluate disease severity, lipase activity, and pancreatic lipase immunoreactivity (PLI) after hospitalization for suspected AP.
One hundred and six client-owned dogs with a minimum of one re-check 2 weeks after hospitalization for AP.
Combined retrospective and prospective study. Clinical signs graded using a clinical disease activity score (CDAS = CIBDAI complemented by abdominal pain) were compared to DGGR-lipase activity (LIPC Roche) and PLI (SpecPL) at 2 weeks (t, n = 106) after discharge. Additional re-checks were available 6 weeks (t, n = 56), 12 weeks (t, n = 24), and 24 weeks (t, n = 13) after discharge.
Lipase activity and PLI correlated strongly at all time points (r 0.863-0.937, p < 0.0001). Discordant results in regard to published reference intervals (RI) were rare (2.8% at t, 1.7% at t, 4.2% at t, 0% at t) and seemed clinically irrelevant. Dogs with still elevated lipase activity and PLI at t (24/106.22.6%) and t (21/56.37.5%) were significantly older compared to dogs with lipase within RI. Weak and moderate correlation between CDAS and lipase activity/PLI was found only at t (r 0.391, p = 0.0009; r 0.279, p = 0.004) and t (r 0.603, p = 0.032; r 0.57 p = 0.045). Most dogs (79.2%) with still elevated lipase at t had no or minimal clinical signs (CDAS 0-3). The same applied to all later re-checks.
Both lipase assays did not differ when compared to clinical status. Most dogs with hyperlipasemia after hospitalization for AP have no or minimal clinical signs.
目前尚无关于犬急性胰腺炎（AP）住院后临床症状与脂肪酶结果对比的数据。
评估疑似AP住院后的疾病严重程度、脂肪酶活性及胰腺脂肪酶免疫反应性（PLI）。
106只客户拥有的犬，AP住院后至少在2周进行一次复查。
回顾性与前瞻性联合研究。将使用临床疾病活动评分（CDAS = CIBDAI加上腹痛）分级的临床症状与出院后2周（时间点t，n = 106）的DGGR - 脂肪酶活性（罗氏LIPC）和PLI（SpecPL）进行比较。出院后6周（时间点t，n = 56）、12周（时间点t，n = 24）和24周（时间点t，n = 13）也可进行额外复查。
所有时间点脂肪酶活性与PLI均呈强相关性（r = 0.863 - 0.937，p < 0.0001）。与已发表的参考区间（RI）不一致的结果很少见（时间点t为2.8%，时间点t为1.7%，时间点t为4.2%，时间点t为0%），且似乎在临床上无相关性。与脂肪酶在RI范围内的犬相比，在时间点t（24/106，22.6%）和时间点t（21/56，37.5%）脂肪酶活性和PLI仍升高的犬年龄显著更大。仅在时间点t（r = 0.391，p = 0.0009；r = 0.279，p = 0.004）和时间点t（r = 0.603，p = 0.032；r = 0.57，p = 0.045）发现CDAS与脂肪酶活性/PLI之间存在弱和中度相关性。在时间点t脂肪酶仍升高的大多数犬（79.2%）无临床症状或症状轻微（CDAS 0 - 3）。所有后续复查情况相同。
与临床状态相比，两种脂肪酶检测方法无差异。AP住院后大多数高脂血症犬无临床症状或症状轻微。
